XML 18 R25.htm IDEA: XBRL DOCUMENT v3.3.0.814
Basis of Presentation (Narrative) (Details)
$ / shares in Units, shares in Millions
 1 Months Ended 3 Months Ended 6 Months Ended 9 Months Ended 12 Months Ended
May. 31, 2014
USD ($)
Jan. 31, 2010
right
Sep. 30, 2015
USD ($)
$ / shares
Jun. 30, 2015
USD ($)
$ / shares
Sep. 30, 2014
USD ($)
$ / shares
Jun. 30, 2015
USD ($)
$ / shares
Sep. 30, 2015
USD ($)
segment
$ / shares
shares
Sep. 30, 2014
USD ($)
$ / shares
shares
Dec. 31, 2014
USD ($)
Aug. 31, 2014
USD ($)
Revision of Immaterial Error                    
Current contingent liabilities     $ 7,620,000       $ 7,620,000   $ 6,796,000  
Net income (loss)     $ 224,539,000   $ 1,280,000   $ 248,857,000 $ 4,969,000    
Net income (loss) (in usd per share) | $ / shares     $ 11.29   $ 0.06   $ 12.61 $ 0.24    
Earnings (Loss) Per Share                    
Common shares excluded from computation | shares             3.3 5.0    
Cash, Cash Equivalents and Short-term Investments                    
Maturity period of cash and cash equivalents, maximum             3 months      
Maturity period of short term investments, minimum             3 months      
Inventory, Net [Abstract]                    
Inventory write downs     $ 0   $ 0   $ 0 $ 0    
Goodwill and Other Identifiable Intangible Assets                    
Finite-lived intangible asset, useful life             20 years      
Amortization expense     600,000   600,000   $ 1,800,000 1,800,000    
Impairment of goodwill     0   0   0 0    
Amortization Expense                    
Amortization expense 2015     2,400,000       2,400,000      
Amortization expense 2016     2,400,000       2,400,000      
Amortization expense 2017     2,400,000       2,400,000      
Amortization expense 2018     2,400,000       2,400,000      
Amortization expense 2019     2,400,000       2,400,000      
Property and Equipment                    
Depreciation     100,000   100,000   $ 200,000 200,000    
Revenue Recognition                    
Restocking fee (percent)             20.00%      
Segment Reporting                    
Number of reportable segments | segment             2      
Minimum                    
Revenue Recognition                    
Period when partner sales reports are received after end of quarter             30 days      
Maximum                    
Revenue Recognition                    
Period when partner sales reports are received after end of quarter             60 days      
Equipment | Minimum                    
Property and Equipment                    
Estimated useful life of assets             3 years      
Equipment | Maximum                    
Property and Equipment                    
Estimated useful life of assets             10 years      
Cydex Pharmaceuticals, Inc                    
Contingent Liabilities                    
Fair value of liability     10,500,000       $ 10,500,000   11,500,000  
Contingent liability change in amount     900,000   2,800,000   3,100,000 5,600,000    
Cydex Pharmaceuticals, Inc | Revenue Sharing                    
Contingent Liabilities                    
Purchase of commercial license rights     800,000   0   3,900,000 1,600,000    
Metabasis Therapeutics                    
Contingent Liabilities                    
Fair value of liability     4,700,000       4,700,000   3,700,000  
Contingent liability change in amount     (3,200,000)   (1,200,000)   1,900,000 700,000    
Number of contingent value rights | right   4                
Number of contingent value rights per series of contingent value rights | right   1                
Number of contingent value rights issued for each share | right   4                
Contingent value rights, frequency of cash payment   6 months                
Contingent liability, cash payment     500,000       800,000      
Omthera Pharmaceuticals                    
Milestone Payments                    
Event-based payment $ 1,000,000                  
Proceeds from Collaborators                 500,000  
Milestone payment received             0   0  
Collaborative Arrangement, Product | Omthera Pharmaceuticals                    
Milestone Payments                    
Event-based payment                 400,000  
2019 convertible senior notes                    
Convertible Debt                    
Principal amount outstanding     245,000,000       245,000,000   $ 245,000,000  
2019 convertible senior notes | Senior Notes                    
Convertible Debt                    
Principal amount outstanding                   $ 245,000,000.0
Interest rate                   0.75%
Acquired in-process research and development                    
Goodwill and Other Identifiable Intangible Assets                    
Impairment of IPR&D     0   $ 0   $ 0 $ 0    
Previously Reported Understatement                    
Revision of Immaterial Error                    
Current contingent liabilities       $ 600,000   $ 600,000        
Previously Reported Overstatement                    
Revision of Immaterial Error                    
Net income (loss)       $ 600,000   $ 600,000        
Net income (loss) (in usd per share) | $ / shares       $ 0.03   $ 0.03        
Impact of Correction                    
Revision of Immaterial Error                    
Net income (loss)     $ (600,000)              
Net income (loss) (in usd per share) | $ / shares     $ (0.03)